ADC Therapeutics SA

ADCT

CIK 0001771910 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$23M
↑+36.4% +$6Mvs FY2024 (Q4)
Gross Profit
$23M
↑+36.4% +$6Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
58/100
  • Profitability
    100ROIC 49.4% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 4.37 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    4Asset Turnover 0.25x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +36.4% (10% = solid, 25%+ = elite)
  • Margin Trend
    45Op Margin -188.5% · trend -0.3pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$264K
investment in PP&E
Stock-based comp (TTM)
$7M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$323M
everything owned
Total liabilities
$509M
everything owed
Stockholders' equity
$-186M
shareholder claim

Recent performance · 12 quarters

Revenue↑+36.4% +$6M
$23M
Net Income↑+6.8% +$3M
$-41M
Free Cash Flow↑+100.0% +$90K
$0
Operating Margin↑+4.1pts
-188.5%

Drill down